title: CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection.
abstract: Primary infection with varicella zoster virus (VZV) results in varicella (more commonly known as chickenpox) after which VZV establishes latency in sensory ganglia. VZV can reactivate to cause herpes zoster (shingles), a debilitating disease that affects one million individuals in the US alone annually. Current vaccines against varicella (Varivax) and herpes zoster (Zostavax) are not 100% efficacious. Specifically, studies have shown that 1 dose of varivax can lead to breakthrough varicella, albeit rarely, in children and a 2-dose regimen is now recommended. Similarly, although Zostavax results in a 50% reduction in HZ cases, a significant number of recipients remain at risk. To design more efficacious vaccines, we need a better understanding of the immune response to VZV. Clinical observations suggest that T cell immunity plays a more critical role in the protection against VZV primary infection and reactivation. However, no studies to date have directly tested this hypothesis due to the scarcity of animal models that recapitulate the immune response to VZV. We have recently shown that SVV infection of rhesus macaques models the hallmarks of primary VZV infection in children. In this study, we used this model to experimentally determine the role of CD4, CD8 and B cell responses in the resolution of primary SVV infection in unvaccinated animals. Data presented in this manuscript show that while CD20 depletion leads to a significant delay and decrease in the antibody response to SVV, loss of B cells does not alter the severity of varicella or the kinetics/magnitude of the T cell response. Loss of CD8 T cells resulted in slightly higher viral loads and prolonged viremia. In contrast, CD4 depletion led to higher viral loads, prolonged viremia and disseminated varicella. CD4 depleted animals also had delayed and reduced antibody and CD8 T cell responses. These results are similar to clinical observations that children with agammaglobulinemia have uncomplicated varicella whereas children with T cell deficiencies are at increased risk of progressive varicella with significant complications. Moreover, our studies indicate that CD4 T cell responses to SVV play a more critical role than antibody or CD8 T cell responses in the control of primary SVV infection and suggest that one potential mechanism for enhancing the efficacy of VZV vaccines is by eliciting robust CD4 T cell responses.
authors.affiliation: Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, United States of America.
authors.forename: Kristen
authors.initials: K
authors.lastname: Haberthur
authors.forename: Flora
authors.initials: F
authors.lastname: Engelmann
authors.forename: Byng
authors.initials: B
authors.lastname: Park
authors.forename: Alex
authors.initials: A
authors.lastname: Barron
authors.forename: Alfred
authors.initials: A
authors.lastname: Legasse
authors.forename: Jesse
authors.initials: J
authors.lastname: Dewane
authors.forename: Miranda
authors.initials: M
authors.lastname: Fischer
authors.forename: Amelia
authors.initials: A
authors.lastname: Kerns
authors.forename: Monica
authors.initials: M
authors.lastname: Brown
authors.forename: Ilhem
authors.initials: I
authors.lastname: Messaoudi
mesh_terms: D000818:Animals; D018951:Antigens, CD20 / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D015704:CD4 Antigens / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002644:Chickenpox / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D019433:Chickenpox Vaccine / Q000276:immunology; D004195:Disease Models, Animal; D006566:Herpesviridae Infections / Q000276:immunology* / Q000821:virology; D014645:Herpesvirus 3, Human / Q000276:immunology*; D008253:Macaca mulatta; D018140:Varicellovirus / Q000276:immunology* / Q000502:physiology; D019562:Viral Load; D014779:Virus Replication
chemical_list: D018951:Antigens, CD20; D015704:CD4 Antigens; D019433:Chickenpox Vaccine
references.citation: J Infect Dis. 1997 Sep;176(3):578-85
references.pmid: 9291302
references.citation: J Virol. 2000 Feb;74(4):1900-7
references.pmid: 10644363
references.citation: N Engl J Med. 1983 Dec 1;309(22):1362-8
references.pmid: 6314138
references.citation: J Pediatr. 1994 Apr;124(4):593-6
references.pmid: 8151475
references.citation: J Med Virol. 2004 Jan;72(1):174-9
references.pmid: 14635028
references.citation: Arch Intern Med. 1982 Feb;142(2):291-3
references.pmid: 6277260
references.citation: J Infect Dis. 2008 Mar 1;197 Suppl 2:S228-36
references.pmid: 18419402
references.citation: J Virol. 2006 Oct;80(19):9772-8
references.pmid: 16973581
references.citation: J Infect Dis. 2005 Jan 15;191(2):198-206
references.pmid: 15609229
references.citation: J Immunol. 1991 Jan 1;146(1):257-64
references.pmid: 1670603
references.citation: J Infect Dis. 1995 Jan;171(1):13-7
references.pmid: 7798653
references.citation: J Infect Dis. 2000 Mar;181(3):859-66
references.pmid: 10720505
references.citation: PLoS Pathog. 2009 Nov;5(11):e1000657
references.pmid: 19911054
references.citation: Adv Vet Sci Comp Med. 1984;28:151-99
references.pmid: 6098169
references.citation: J Virol. 1986 Apr;58(1):179-84
references.pmid: 3005647
references.citation: J Infect Dis. 2007 Mar 1;195(5):660-4
references.pmid: 17262706
references.citation: Virology. 1992 Feb;186(2):562-72
references.pmid: 1310185
references.citation: Clin Microbiol Rev. 1996 Jul;9(3):361-81
references.pmid: 8809466
references.citation: J Infect Dis. 1992 Jan;165(1):119-26
references.pmid: 1309369
references.citation: Clin Transplant. 2010 May-Jun;24(3):401-9
references.pmid: 19222507
references.citation: J Infect Dis. 1980 Sep;142(3):414-20
references.pmid: 6255038
references.citation: Medicine (Baltimore). 1982 Sep;61(5):310-6
references.pmid: 6981045
references.citation: J Infect Dis. 2008 Mar 1;197(5):654-7
references.pmid: 18260763
references.citation: J Infect Dis. 2008 Mar 15;197(6):825-35
references.pmid: 18419349
references.citation: J Pediatr. 1984 Aug;105(2):200-5
references.pmid: 6086866
references.citation: Viral Immunol. 1989 Fall;2(3):175-84
references.pmid: 2483504
references.citation: Biol Blood Marrow Transplant. 2000;6(3):219-30
references.pmid: 10871147
references.citation: J Infect Dis. 1984 May;149(5):741-9
references.pmid: 6327848
references.citation: J Virol. 1987 Nov;61(11):3463-9
references.pmid: 2822954
references.citation: Antimicrob Agents Chemother. 1981 Sep;20(3):291-7
references.pmid: 7305319
references.citation: Invest Ophthalmol Vis Sci. 2009 Feb;50(2):743-51
references.pmid: 18936136
references.citation: Vaccine. 2010 Aug 16;28(36):5878-82
references.pmid: 20600487
references.citation: J Med Virol. 2003;70 Suppl 1:S4-8
references.pmid: 12627479
references.citation: Microb Pathog. 1993 Aug;15(2):141-51
references.pmid: 8255207
references.citation: Infect Immun. 1981 Apr;32(1):24-7
references.pmid: 6163722
references.citation: Virology. 1984 Jul 15;136(1):241-6
references.pmid: 6330994
references.citation: J Infect Dis. 1992 Aug;166 Suppl 1:S48-50
references.pmid: 1320650
references.citation: Front Biosci. 1999 Feb 15;4:D200-11
references.pmid: 9989948
references.citation: J Infect Dis. 2003 Jul 1;188(1):40-52
references.pmid: 12825169
references.citation: Pediatrics. 2011 Aug;128(2):214-20
references.pmid: 21788222
references.citation: Semin Immunol. 2001 Feb;13(1):27-39
references.pmid: 11289797
references.citation: N Engl J Med. 1974 Jan 31;290(5):243-5
references.pmid: 4358055
references.citation: J Gen Intern Med. 2005 Aug;20(8):748-53
references.pmid: 16050886
references.citation: J Infect Dis. 1998 Jun;177(6):1701-4
references.pmid: 9607852
references.citation: Nature. 2009 Nov 26;462(7272):510-3
references.pmid: 19898495
references.citation: J Exp Med. 2004 Oct 4;200(7):917-25
references.pmid: 15452178
references.citation: Neurology. 2008 Mar 11;70(11):853-60
references.pmid: 18332343
references.citation: Neurol Clin. 2008 Aug;26(3):675-97, viii
references.pmid: 18657721
references.citation: Infect Dis Clin North Am. 1996 Sep;10(3):529-70
references.pmid: 8856351
references.citation: N Engl J Med. 2005 Jun 2;352(22):2271-84
references.pmid: 15930418
references.citation: J Virol. 2002 Sep;76(17):8548-50
references.pmid: 12163574
references.citation: J Infect Dis. 2004 Jul 1;190(1):72-82
references.pmid: 15195245
references.citation: J Immunol. 1989 Jan 15;142(2):636-41
references.pmid: 2536059
references.citation: Pediatr Infect Dis J. 1989 Sep;8(9):586-90
references.pmid: 2797953
references.citation: N Engl J Med. 1969 May 29;280(22):1191-4
references.pmid: 4181206
references.citation: J Virol. 2005 Mar;79(5):2651-8
references.pmid: 15708984
references.citation: Clin Infect Dis. 2001 May 15;32(10):1481-6
references.pmid: 11317250
references.citation: Ann N Y Acad Sci. 1992 Jun 16;653:323-33
references.pmid: 1320844
references.citation: J Infect Dis. 1978 May;137(5):531-40
references.pmid: 207782
references.citation: Virology. 2001 May 25;284(1):123-30
references.pmid: 11352673
references.citation: J Am Osteopath Assoc. 2009 Jun;109(6 Suppl 2):S2-6
references.pmid: 19553632
references.citation: J Infect Dis. 1991 Apr;163(4):746-51
references.pmid: 1849161
references.citation: J Virol. 2002 Nov;76(22):11425-33
references.pmid: 12388703
references.citation: J Infect Dis. 1986 Sep;154(3):422-9
references.pmid: 3016110
references.citation: J Pediatr. 1981 Mar;98(3):368-73
references.pmid: 7205447
references.citation: Exp Eye Res. 2006 Jul;83(1):69-75
references.pmid: 16530754